Diatide AcuTect clinical outcomes trial would help clarify imaging agent use, panel recommends.
This article was originally published in The Gray Sheet
Executive Summary
DIATIDE ACUTECT PHASE IV CLINICAL OUTCOMES STUDY would help to define the clinical use of the imaging agent after approval, FDA's Medical Imaging Drugs Advisory Committee suggested at a Feb. 9 review of the AcuTect (Tc 99 apcitide) new drug application for approval for use in scintigraphic imaging of acute venous thrombosis.